ROBLES, N. R. et al. Anti-hipertensive effect of eprosartan in diabetic patients. []. , 21, 5, pp.23-26. ISSN 0212-7199.

Objective: Diabetes mellitus seems to induce an special dificulty to control de la high blood pressure. This effect is more severe on the SBP. Previous reports suggest that a new angiotensin receptor blocker, eprosartan, might have a higher efficacy to reduce SBP. It has been evaluated the BP decrease obtained with eprosartan in a group of diabetics patients compared to non diabetic patients. Materialand methods: 81 patients were recruited of whom 65 have ended follow-up. 34 patients were diabetics (mean age 66.7±10.7 years, 15 men and 19 women) and 31 were non diabetics control patients (mean age 61.8±12,8 years, 13 men and 18 women). All patients were treated with (600 mg) once daily. The dosis was ingested in the morning. They were made three follow up visits (1, 3 and 6 mo after the first visit). Results: SBP was significantly decreased both in diabetics (baseline 170.9±12.0, final 139.1±13.0 mmHg, p < 0.001) and in non diabetics group (baseline 169.9±18.0, final 142.0±13.3 mmHg, p < 0.001). DBP was also reduced in both groups (diabetics: baseline 92.9±9.7, final 78.4±8.5 mmHg, p < 0.001; non diabetics: baseline 95.6±7.9, final 79.1±7.4 mmHg, p < 0.001). Differences between the groups were not significant in any visit. Final BP reduction reached was -31.7/-14.6 mmHg in diabetics vs -27,6/-16,5 mmHg in non diabetics patients (difference is not significant) Pulse pressure changes were not different between the twp groups (diabetics, 17.8±14.5, vs non diabetics, 11.1±13.2 mmHg).Two diabetic patients need a second drug to achieve BP goal and no one innon diabetic group. No adverse effects were reported. Conclusions: Eprosartan seems to be an effective drug to reduce SBP, DBP and pulse pressure with the same effectiveness in diabetics and non diabetic patients.

: Hypertension; Eprosartan; Diabetes mellitus.

        · |     · |     · ( pdf )